1,032 results match your criteria Drug-Induced Pulmonary Toxicity


Comprehensive Analysis of Metabolic Changes in Male Mice Exposed to Sodium Valproate Based on GC-MS Analysis.

Drug Des Devel Ther 2022 17;16:1915-1930. Epub 2022 Jun 17.

Department of Neurosurgery, Affiliated Hospital of Jining Medical University, Jining, People's Republic of China.

Purpose: Sodium valproate (VPA) is the most widely used broad-spectrum antiepileptic first-line drug in clinical practice and is effective against various types of epilepsy. However, VPA can induce severe cardiotoxicity, nephrotoxicity, hepatotoxicity, and neurotoxicity, which limits its use. Metabolomic studies of VPA-induced toxicity have focused primarily on changes in serum and urine metabolites but have not evaluated changes in major organs or tissues. Read More

View Article and Full-Text PDF

Acute Multi-Organ Toxicity During 24-Hour Dosing of Intravenous Amiodarone: A Case Report.

Cureus 2022 May 15;14(5):e25028. Epub 2022 May 15.

Family Medicine, Desert Regional Medical Center, Palm Springs, USA.

We present a unique case of a 60-year-old male with congestive heart failure who was admitted for a pre-syncopal episode and found to be in atrial fibrillation with rapid ventricular response (RVR). In order to effectively rate control the patient, he was administered an amiodarone bolus and intravenous (IV) infusion over 24 hours, along with a single oral 200 mg dose the following day. The patient subsequently developed acute hepatotoxicity along with features of acute kidney injury (AKI), pulmonary distress, and leukocytosis. Read More

View Article and Full-Text PDF

Comparison of Pneumonitis Rates and Severity in Patients With Lung Cancer Treated by Immunotherapy, Radiotherapy, and Immunoradiotherapy.

Cureus 2022 Jun 5;14(6):e25665. Epub 2022 Jun 5.

Hematology and Medical Oncology, St. Luke's University Health Network, Bethlehem, USA.

Introduction Radiation pneumonitis (RP) is a common dose-limiting toxicity of radiotherapy to the chest in lung cancer patients. Similarly, the revolutionary use of immune checkpoint inhibitors (ICIs) to treat lung cancer can be complicated by immune-related adverse events (irAEs), particularly checkpoint inhibitor pneumonitis (CIP). Our study aimed to assess the effect of immunotherapy, with and without radiotherapy, on pneumonitis and other outcomes. Read More

View Article and Full-Text PDF

Venlafaxine-induced interstitial lung disease with COVID-19 pandemic-related depression.

Clin Case Rep 2022 Jun 2;10(6):e05941. Epub 2022 Jun 2.

Department of Psychiatry Kaga Mental Hospital Kaga Japan.

Venlafaxine-associated pulmonary toxicity is rare, with only a few reports of pneumonitis, eosinophilic pneumonia, and asthma. We report a case of venlafaxine-induced interstitial lung disease in a patient with coronavirus disease 2019 pandemic-related depression. Chest imaging findings improved after discontinuation of venlafaxine and treatment with corticosteroids. Read More

View Article and Full-Text PDF

Pulmonary toxicity in driver gene positive non-small cell lung cancer therapy.

Curr Med Res Opin 2022 Jun 15:1-10. Epub 2022 Jun 15.

Department of Thoracic Surgery, The Second Affiliated Hospital of Zhengzhou University, Zhengzhou, China.

Molecular targeted therapy significantly improved the therapeutic efficacy in non-small cell lung cancer (NSCLC) patients with driver gene mutations but also with new toxicity profiles. Although most patients treated with these drugs developed relatively controllable toxicity, significant pulmonary toxicity events, including interstitial lung disease, occurred in a small proportion of patients and can lead to discontinuation or even be life-threatening. Pulmonary toxicity associated with these anti-tumor drugs is a problem that cannot be ignored in clinical practice. Read More

View Article and Full-Text PDF

A drug-responsive multicellular human spheroid model to recapitulate drug-induced pulmonary fibrosis.

Biomed Mater 2022 06 9;17(4). Epub 2022 Jun 9.

Department of Bioengineering, Faculty of Engineering, Ege University, 35100 Izmir, Turkey.

Associated with a high mortality rate, pulmonary fibrosis (PF) is the end stage of several interstitial lung diseases. Although many factors are linked to PF progression, initiation of the fibrotic process remains to be studied. Current research focused on generating new strategies to gain a better understanding of the underlying disease mechanism as the animal models remain insufficient to reflect human physiology. Read More

View Article and Full-Text PDF

Intestinal Haemorrhage and Colitis Induced by Treatment With Osimertinib for Non-Small-Cell Lung Carcinoma: A Case Report.

Front Pharmacol 2022 5;13:854277. Epub 2022 Apr 5.

Department of Radiology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.

Osimertinib is recommended either as the first-line therapy for sensitizing EGFR-mutations (FLAURA trial) or at progression to first-/second-generation EGFR inhibitors in the presence of resistance mutation T790M (AURA 3 study). It can effectively improve the prognosis of patients with NSCLC with manageable adverse reactions. Among adverse events, intestinal haemorrhage is rare and requires extensive study on its potential lethality. Read More

View Article and Full-Text PDF

An Unusual Case of Lorlatinib-Induced Pneumonitis: A Case Report.

Case Rep Oncol 2022 Jan-Apr;15(1):225-230. Epub 2022 Mar 14.

Department of Medical Oncology, Wagga Wagga Base Hospital, Wagga Wagga, New South Wales, Australia.

The discovery of tyrosine kinase oncogenic driver mutations, including anaplastic lymphoma kinase (ALK), has changed the face of non-small cell lung cancer (NSCLC) treatment. Whilst the development of tyrosine kinase inhibitors has improved survival, with their increasing use, it is important to be aware of the risks of rare yet serious adverse events, such as drug-induced pulmonary toxicity. Whilst little is known in regard to drug-induced pneumonitis in the setting of ALK inhibitors, such reactions carry a high morbidity and mortality rate, impacting greatly upon options for further treatment and management. Read More

View Article and Full-Text PDF

Cardiorenal Syndrome Triggered by Slowly Progressive Drugs Toxicity-Induced Renal Failure along with Minimal Mitral Disease: A Case Report.

Endocr Metab Immune Disord Drug Targets 2022 Apr 12. Epub 2022 Apr 12.

Department of Emergency and Organ Transplantation, Unit of Cardiovascular Diseases, University of Bari, Bari, Italy.

Background: We report the case of a 93-year-old patient with normal left ventricular function and severe mitral annulus calcification, with mild mitral steno-insufficiency.

Case Presentation: She had developed creeping drugs-induced renal toxicity that is generally totally overlooked, due mainly to statins, a proton pump inhibitor, and aspirin. The Na and fluid retention, along with hypertension that ensued, although not severe, caused acute heart failure (sub-pulmonary edema) by worsening the mitral insufficiency. Read More

View Article and Full-Text PDF

Drug-induced interstitial lung disease.

Eur Respir J 2022 Mar 24. Epub 2022 Mar 24.

Department of Respiratory Medicine, National Coordinating Reference Center for Rare Pulmonary Diseases, Louis Pradel Hospital, Hospices Civils de Lyon, member of ERN-Lung, Lyon, France.

Interstitial lung disease (ILD) secondary to drug-induced lung injury is an increasingly common cause of morbidity and mortality. The number of drugs associated with the development of ILD continues to raise, mainly due to the use of novel monoclonal antibodies and biologics for neoplastic and rheumatologic diseases, and includes, among others, chemotherapeutics, molecular targeting agents, immune checkpoint inhibitors, antibiotics, antiarrhythmics, and conventional or biologic disease-modifying antirheumatic drugs. Drug-induced ILD (DI-ILD) manifests with a variety of clinical patterns, ranging from mild respiratory symptoms to rapidly progressive respiratory failure and death. Read More

View Article and Full-Text PDF

Bosutinib-induced lung injury: a report of two cases and literature review.

Int J Hematol 2022 Jun 28;115(6):902-905. Epub 2022 Feb 28.

Department of Hematology, Juntendo University School of Medicine, 2-1-1 Hongo, Bunkyo-ku, Tokyo, 113-8421, Japan.

The prognosis of patients with chronic myeloid leukemia (CML) has improved dramatically since the development of tyrosine kinase inhibitors (TKIs). Three second-generation TKIs, including bosutinib, are currently approved for treatment of CML, and show a faster and deeper clinical response than imatinib. Common adverse events (AEs) of bosutinib are diarrhea and hepatic toxicity; however, lung complications are rare. Read More

View Article and Full-Text PDF

Mechanism of Lethal Skin Toxicities Induced by Epidermal Growth Factor Receptor Inhibitors and Related Treatment Strategies.

Front Oncol 2022 10;12:804212. Epub 2022 Feb 10.

Department of Pharmacy, Daping Hospital, Army Medical University, Chongqing, China.

Epidermal growth factor receptor (EGFR) inhibitors are widely used to treat various types of cancers such as non-small cell lung cancer, head and neck cancer, breast cancer, pancreatic cancer. Adverse reactions such as skin toxicity, interstitial lung disease, hepatotoxicity, ocular toxicity, hypomagnesemia, stomatitis, and diarrhea may occur during treatment. Because the EGFR signaling pathway is important for maintaining normal physiological skin function. Read More

View Article and Full-Text PDF
February 2022

ExoU Induces Lung Endothelial Cell Damage and Activates Pro-Inflammatory Caspase-1 during Infection.

Toxins (Basel) 2022 02 18;14(2). Epub 2022 Feb 18.

Department of Microbiology and Immunology, College of Medicine, University of South Alabama, Mobile, AL 36688, USA.

The Gram-negative, opportunistic pathogen utilizes a type III secretion system to inject exoenzyme effectors into a target host cell. Of the four best-studied exoenzymes, ExoU causes rapid cell damage and death. ExoU is a phospholipase A (PLA) that hydrolyses host cell membranes, and strains expressing ExoU are associated with poor outcomes in critically ill patients with pneumonia. Read More

View Article and Full-Text PDF
February 2022

TRPV1 Protect against Hyperglycemia and Hyperlipidemia Induced Liver Injury via OPA1 in Diabetes.

Tohoku J Exp Med 2022 02;256(2):131-139

Department of Cardiology, Chongqing Renji Hospital, University of Chinese Academy of Sciences.

Type 2 diabetes mellitus (T2DM)-associated mitochondrial impairment may a key factor leading to liver injury. Transient receptor potential receptor vanilloid 1 (TRPV1) regulates the energy expenditure and cholesterol metabolism in hepatocytes and protects against oxidative toxicity. Optic atrophy 1 (OPA1) is involved in the protection of TRPV1 on cardiac microvascular and lung injury. Read More

View Article and Full-Text PDF
February 2022

Dissecting the Crosstalk Between Nrf2 and NF-κB Response Pathways in Drug-Induced Toxicity.

Front Cell Dev Biol 2021 2;9:809952. Epub 2022 Feb 2.

Department of Pharmacy, The Second Xiangya Hospital, Central South University, Changsha, China.

Nrf2 and NF-κB are important regulators of the response to oxidative stress and inflammation in the body. Previous pharmacological and genetic studies have confirmed crosstalk between the two. The deficiency of Nrf2 elevates the expression of NF-κB, leading to increased production of inflammatory factors, while NF-κB can affect the expression of downstream target genes by regulating the transcription and activity of Nrf2. Read More

View Article and Full-Text PDF
February 2022

Mechanism of hepatobiliary toxicity of the LPA antagonist BMS-986020 developed to treat idiopathic pulmonary fibrosis: Contrasts with BMS-986234 and BMS-986278.

Toxicol Appl Pharmacol 2022 03 26;438:115885. Epub 2022 Jan 26.

Pharmaceutical Candidate Optimization, Bristol Myers Squibb, Princeton, NJ, USA.

In a Phase 2 clinical trial, BMS-986020, a lysophosphatidic acid receptor-1 (LPA) antagonist, produced hepatobiliary toxicity (increased ALT, AST, and ALP; cholecystitis) and increases in plasma bile acids (BA). Nonclinical investigations conducted to identify a potential mechanism(s) for this toxicity examined BMS-986020 and two LPA antagonists structurally distinct from BMS-986020 (BMS-986234 and BMS-986278). BMS-986020 inhibited hepatic BA efflux transporters BSEP (IC 1. Read More

View Article and Full-Text PDF

Kupffer cells play a crucial role in monocrotaline-induced liver injury by producing TNF-α.

Toxicology 2022 02 19;468:153101. Epub 2022 Jan 19.

State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China; University of Chinese Academy of Sciences, Beijing 100049, China; Zhongshan Branch, the Institute of Drug Discovery and Development, Chinese Academy of Sciences, China. Electronic address:

Monocrotaline (MCT), an unsaturated pyrrolizidine alkaloid (PA) in plants, is mainly toxic to the lung and liver of mammals. As a commonly used tool for liver injury model, the mechanism of MCT hepatoxicity has still not been fully clarified. Kupffer cells (KCs) are the liver-resident macrophages and have various responses to different toxicants and liver damage. Read More

View Article and Full-Text PDF
February 2022

Structure dependence and species sensitivity of in vivo hepatobiliary toxicity with lysophosphatidic acid receptor 1 (LPA) antagonists.

Toxicol Appl Pharmacol 2022 03 31;438:115846. Epub 2021 Dec 31.

Global Regulatory Strategy and Policy, Bristol-Myers Squibb, Princeton, NJ, USA.

BMS-986020, BMS-986234 and BMS-986278, are three lysophosphatidic acid receptor 1 (LPA) antagonists that were or are being investigated for treatment of idiopathic pulmonary fibrosis (IPF). Hepatobiliary toxicity (elevated serum AST, ALT, and ALP, plasma bile acids [BAs], and cholecystitis) was observed in a Phase 2 clinical trial with BMS-986020, and development was discontinued. In dogs and rats, the species used for the pivotal toxicology studies, there was no evidence of hepatobiliary toxicity in the dog while findings in the rat were limited to increased plasma BAs levels (6. Read More

View Article and Full-Text PDF

The efficacy of Jujube syrup on the prevention of drug-induced hepatotoxicity in pulmonary tuberculosis patients: A pilot randomized double-blind placebo-controlled clinical trial.

Pharmacol Res Perspect 2022 02;10(1):e00902

Department of Biostatistics, Health Management and Social Development Research Center, Golestan University of Medical Sciences, Gorgan, Iran.

Liver injury is the most common complication of anti-tuberculosis drugs that can cause significant problems. The study aimed to determine the effectiveness of Jujube syrup on the prevention of antituberculosis drug-induced hepatotoxicity (DIH). This pilot randomized double-blind study was conducted based on a placebo-controlled design in patients with tuberculosis (TB). Read More

View Article and Full-Text PDF
February 2022

Pirfenidone attenuates acetaminophen-induced liver injury via suppressing c-Jun N-terminal kinase phosphorylation.

Toxicol Appl Pharmacol 2022 01 8;434:115817. Epub 2021 Dec 8.

Department of Medicine and Bioregulatory Science, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka 812-8582, Japan.

Acetaminophen (APAP)-induced liver injury is the most frequent cause of acute liver failure in Western countries. Pirfenidone (PFD), an orally bioavailable pyridone derivative, is clinically used for idiopathic pulmonary fibrosis treatment and has antifibrotic, anti-inflammatory, and antioxidant effects. Here we examined the PFD effect on APAP-induced liver injury. Read More

View Article and Full-Text PDF
January 2022

Steatosis, Steatohepatitis and Cancer Immunotherapy: An Intricate Story.

Int J Mol Sci 2021 Nov 30;22(23). Epub 2021 Nov 30.

Department of Clinical Medicine and Surgery, Federico II University, Medical School of Naples, 80131 Naples, Italy.

Immune checkpoint inhibitors represent one of the most significant recent advances in clinical oncology, since they dramatically improved the prognosis of deadly cancers such as melanomas and lung cancer. Treatment with these drugs may be complicated by the occurrence of clinically-relevant adverse drug reactions, most of which are immune-mediated, such as pneumonitis, colitis, endocrinopathies, nephritis, Stevens Johnson syndrome and toxic epidermal necrolysis. Drug-induced steatosis and steatohepatitis are not included among the typical forms of cancer immunotherapy-induced liver toxicity, which, instead, usually occurs as a panlobular hepatitis with prominent lymphocytic infiltrates. Read More

View Article and Full-Text PDF
November 2021

Acute fibrinous and organizing pneumonia complicated with hemophagocytic lymphohistiocytosis caused by chronic active Epstein-Barr virus infection: a case report.

BMC Infect Dis 2021 Dec 4;21(1):1207. Epub 2021 Dec 4.

Department of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine, China-Japan Friendship Hospital, National Clinical Research Center for Respiratory Diseases, No 2, East Yinghua Road, Chaoyang District, Beijing, 100029, China.

Background: Acute fibrinous and organizing pneumonia (AFOP) is a rare lung condition that is associated with acute lung injury. Its etiology may be idiopathic or secondary to a series of conditions, including immune-related diseases, unclassified connective tissue diseases, hematopoietic stem cell transplantation, infections, hematological diseases and drug induced lung toxicity. We report for the first time a case of AFOP complicated with hemophagocytic lymphohistiocytosis (HLH) caused by chronic active Epstein-Barr virus (CAEBV) infection. Read More

View Article and Full-Text PDF
December 2021

Role of IL-6/STAT3 pathway in mediating the protective effect of agomelatine against methotrexate-induced lung/intestinal tissues damage in rats.

Immunopharmacol Immunotoxicol 2022 Feb 12;44(1):35-46. Epub 2021 Nov 12.

Department of Pharmacology, Faculty of Medicine, Minia University, Minia, Egypt.

Background: Methotrexate (MTX), an anticancer drug, has been linked to multiple organ toxicity. The drug-induced acute toxic symptoms can negatively affect the patient's commitment to the course of treatment.

Materials And Methods: This study aimed to investigate the mitigating action of agomelatine (Ago) against MTX-induced lung and intestinal toxicity. Read More

View Article and Full-Text PDF
February 2022

Sertraline-Associated Interstitial Lung Disease: A case series and Literature Review.

Sarcoidosis Vasc Diffuse Lung Dis 2021 30;38(3):e2021027. Epub 2021 Sep 30.

Pulmonary Institute, Rabin Medical Center, Petah Tikva, Israel.

Sertraline-associated interstitial lung disease (ILD) is a rare entity. A search of the English medical literature retrieved only 9 such cases. We report herein on an additional 12 patients who developed ILD during treatment with sertraline. Read More

View Article and Full-Text PDF
September 2021

Animal models of drug-induced pulmonary fibrosis: an overview of molecular mechanisms and characteristics.

Cell Biol Toxicol 2021 Nov 5. Epub 2021 Nov 5.

Department of Pharmacology, School of Basic Medical Sciences, Zhejiang University, Hangzhou, 310058, China.

Idiopathic pulmonary fibrosis (IPF) is a progressive interstitial lung disease characterized by progressive loss of pulmonary function. Drug-induced interstitial lung disease has been reported as a severe adverse effect of some drugs, such as bleomycin, amiodarone, and methotrexate. Based on good characteristics, drug-induced pulmonary fibrosis (PF) animal model has played a key role in our understanding of the molecular mechanisms of PF pathogenesis and recapitulates the specific pathology in patients and helps develop therapeutic strategies. Read More

View Article and Full-Text PDF
November 2021

Fomepizole as an adjunct in acetylcysteine treated acetaminophen overdose patients: a case series.

Clin Toxicol (Phila) 2022 Apr 28;60(4):472-477. Epub 2021 Oct 28.

Departments of Emergency Medicine and Pediatrics, University of Colorado School of Medicine, Aurora, CO, USA.

Introduction: Acetaminophen (N-acetyl-para-aminophenol or APAP) is the leading cause of acute liver failure worldwide. Standard therapy for APAP overdose is with IV N-acetylcysteine (NAC). However, overdose patients treated with NAC can still incur hepatotoxicity in some circumstances. Read More

View Article and Full-Text PDF

Drug-induced pulmonary toxicity in breast cancer patients treated with systemic therapy: a systematic literature review.

Expert Rev Anticancer Ther 2021 12 2;21(12):1399-1410. Epub 2021 Nov 2.

Department of Medical Oncology, Cancer Hospital Chinese Academy of Medical Sciences, Beijing, China.

Introduction: Drug-induced pulmonary toxicity (DIPT) associated with breast cancer (BC) therapy has been a major concern in recent times. DIPT may not be attributed to a single type of therapy because of the concomitant use of other anticancer drugs or along with radiotherapy, which is an independent risk factor for pulmonary toxicity.

Areas Covered: In this systematic literature review, we evaluated the probable cause and prevalence of DIPT in various systemic therapies used in BC treatment. Read More

View Article and Full-Text PDF
December 2021

Interstitial Lung Disease Induced by Anti-ERBB2 Antibody-Drug Conjugates: A Review.

JAMA Oncol 2021 Dec;7(12):1873-1881

Division of Early Drug Development, European Institute of Oncology IRCCS, Milan, Italy.

Importance: In the past decade, ERBB2 (formerly HER2)-directed antibody-drug conjugates (ADCs) have substantially changed treatment of both advanced and early-stage ERBB2-positive breast cancer. Novel conjugates are now showing activity in trials of other ERBB2-associated tumors, leading to the recent US Food and Drug Administration approval of trastuzumab deruxtecan for ERBB2-positive gastric cancer, as well as beneficial results in colorectal, lung, and bladder cancer. It is thus possible that anti-ERBB2 ADCs may become a treatment option for multiple types of tumors because many have at least some expression of ERBB2. Read More

View Article and Full-Text PDF
December 2021

Role of Drug-Gene Interactions and Pharmacogenetics in Simvastatin-Associated Pulmonary Toxicity.

Drug Saf 2021 11 4;44(11):1179-1191. Epub 2021 Oct 4.

ILD Care Foundation Research Team, Ede, The Netherlands.

Introduction: Simvastatin has previously been associated with drug-induced interstitial lung disease. In this retrospective observational study, cases with non-specific interstitial pneumonia (NSIP) or idiopathic pulmonary fibrosis (IPF) with simvastatin-associated pulmonary toxicity (n = 34) were evaluated.

Objective: To identify whether variations in genes encoding cytochrome P450 (CYP) enzymes or in the SLCO1B1 gene (Solute Carrier Organic anion transporting polypeptide 1B1 gene, encoding the organic anion transporting polypeptide 1B1 [OATP1B1] drug transporter enzyme), and/or characteristics of concomitantly used drugs, predispose patients to simvastatin-associated pulmonary toxicity. Read More

View Article and Full-Text PDF
November 2021

Carfilzomib-associated pulmonary arterial hypertension in multiple myeloma.

Pulm Circ 2021 Oct-Dec;11(4):20458940211049300. Epub 2021 Sep 29.

Division of Pulmonary, Critical Care and Sleep Medicine, Department of Medicine, University of California San Diego, La Jolla, CA, USA.

Drug-induced pulmonary arterial hypertension (PAH) is constantly evolving as new drugs are developed. Carfilzomib is a recently approved therapy for relapsed and refractory multiple myeloma. While it has been associated with cardiovascular adverse events, such as ischemic heart disease and heart failure, PAH has not been a well-described side effect. Read More

View Article and Full-Text PDF
September 2021